Calling upon all public health mycologists: To accompany the country burden papers from 14 countries
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Since 2013, the Leading International Fungal Education (LIFE) portal has facilitated the estimation of the burden of serious fungal infections country by country for over 5.7 billion people (>80% of the world’s population).”
From Global and Multi-National Prevalence of Fungal Diseases-Estimate Precision (2017) · cites this paper as [14]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vos, T., Flaxman, A. D., Naghavi, M., Lozano, R., Michaud, C., Ezzati, M., Shibuya, K., Salomon, J. A., Abdalla, S., Aboyans, V., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61729-2 · Cited by 8,291
Yiannakis, E. P., & Boswell, T. C. (2016) · Journal of Hospital Infection · doi:10.1016/j.jhin.2016.01.018 · Cited by 99 · cited 1×
“Multiple outbreaks are described, typically in transplant patients [3].”
BackgroundFungal Disease in Britain and the United States 1850–2000 : Mycoses and Modernity
Homei, A., & Worboys, M. (2013) · Palgrave Macmillan eBooks · doi:10.26530/oapen_474551 · Cited by 37
Fungal Disease in Britain and the United States 1850–2000
Homei, A., & Worboys, M. (2013) · Palgrave Macmillan UK eBooks · doi:10.1057/9781137377029 · Cited by 21
Cited by
Global and Multi-National Prevalence of Fungal Diseases-Estimate Precision
Bongomin, F., Gago, S., Oladele, R., & Denning, D. (2017) · Journal of Fungi · doi:10.3390/jof3040057 · Cited by 2,953
“7 billion people (>80% of the world’s population) (Figure 1) [14].”
Self-citationEvolution of the human pathogenic lifestyle in fungi
Rokas, A. (2022) · Nature Microbiology · doi:10.1038/s41564-022-01112-0 · Cited by 232
Molecular diagnostics in medical mycology
Wickes, B. L., & Wiederhold, N. P. (2018) · Nature Communications · doi:10.1038/s41467-018-07556-5 · Cited by 188
The fungal cell wall as a target for the development of new antifungal therapies
Cortés, J. C. G., Curto, M.-Á., Carvalho, V. S. D., Pérez, P., & Ribas, J. C. (2019) · Biotechnology Advances · doi:10.1016/j.biotechadv.2019.02.008 · Cited by 170
Geddes‐McAlister, J., & Shapiro, R. S. (2019) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.13739 · Cited by 159
“This is achieved by noncompetitively inhibiting the plasma membrane-bound -(1,3)-d-glucan synthase enzyme complex associated with synthesis of the structural polymer -(1,3)-d-glucan, causing osmotic instability and fungal cell death.”
BackgroundA CRISPR Interference Platform for Efficient Genetic Repression in Candida albicans
Wensing, L. F., Sharma, J., Uthayakumar, D., Proteau, Y., Chavez, A., & Shapiro, R. S. (2019) · mSphere · doi:10.1128/msphere.00002-19 · Cited by 76
Novel mouse monoclonal antibodies specifically recognizing β-(1→3)-D-glucan antigen
Matveev, A. L., Krylov, V. B., Khlusevich, Y. A., Baykov, I. K., Yashunsky, D. V., Emelyanova, L. A., Tsvetkov, Y. E., Karelin, A. A., Bardashova, A. V., Wong, S. S. W., et al. (2019) · PLOS ONE · doi:10.1371/journal.pone.0215535 · Cited by 68
“The incidence of invasive fungal infections continues to increase, and successful treatment of the diseases remains a serious problem despite the development of more effective antifungal preparations with reduced toxicity [1,2].”
Immunotherapy against Systemic Fungal Infections Based on Monoclonal Antibodies
Boniche-Alfaro, C., Rossi, S. A., Kischkel, B., Barbalho, F. V., Moura, Á. N. D., Nosanchuk, J. D., Travassos, L. R., & Taborda, C. P. (2020) · Journal of Fungi · doi:10.3390/jof6010031 · Cited by 65
Peyclit, L., Yousfi, H., Rolain, J., & Bittar, F. (2021) · Pharmaceuticals · doi:10.3390/ph14050488 · Cited by 65
“Most public health organizations, including the World Health Organization, do not have a fungal infection surveillance program, despite the fact that invasive fungal infections present a high mortality rate worldwide, often exceeding 50% [1,2].”
BackgroundRokas, A., Mead, M. E., Steenwyk, J. L., Oberlies, N. H., & Goldman, G. H. (2020) · PLOS Pathogens · doi:10.1371/journal.ppat.1008315 · Cited by 50
“Collectively, Aspergillus fungi affect millions of patients and cause hundreds of thousands of life-threatening infections every year [8, 9].”
BackgroundDeep fungal infections diagnosed by histology in Uganda: a 70-year retrospective study
Kwizera, R., Bongomin, F., & Lukande, R. L. (2020) · Medical Mycology · doi:10.1093/mmy/myaa018 · Cited by 39
Oladele, R. O., Otu, A. A., Olubamwo, O., Makanjuola, O. B., Ochang, E. A., Ejembi, J., Irurhe, N., Ajanaku, I., Ekundayo, H. A., Olayinka, A., et al. (2020) · Pan African Medical Journal · doi:10.11604/pamj.2020.36.297.23279 · Cited by 40
“In reality, the index of suspicion of IFI is usually low and the diagnosis is delayed or completely missed [18].”
BackgroundSelf-citationRecovery from serious fungal infections should be realisable for everyone
Tudela, J. L. R., & Denning, D. W. (2017) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(17)30319-5 · Cited by 40
Self-citationNanopore Sequencing of the Fungal Intergenic Spacer Sequence as a Potential Rapid Diagnostic Assay
Morrison, G. A., Fu, J., Lee, G. C., Wiederhold, N. P., Cañete-Gibas, C. F., Bunnik, E. M., & Wickes, B. L. (2020) · Journal of Clinical Microbiology · doi:10.1128/jcm.01972-20 · Cited by 42
Comprehensive genetic analysis of adhesin proteins and their role in virulence ofCandida albicans
Rosiana, S., Zhang, L., Kim, G. H., Revtovich, A. V., Uthayakumar, D., Sukumaran, A., Geddes‐McAlister, J., Kirienko, N. V., & Shapiro, R. S. (2021) · Genetics · doi:10.1093/genetics/iyab003 · Cited by 43
“Fungal pathogens have been emerging as a significant threat to human health, resulting in over 1.6 million deaths worldwide each year (Bongomin et al. 2017; Denning 2017; Geddes-McAlister and Shapiro 2019).”
BackgroundInfluentialLaser-assisted uvulopalatoplasty (LAUP) complications and side effects: a systematic review
Wischhusen, J. D., Qureshi, U., & Camacho, M. (2019) · Nature and Science of Sleep · doi:10.2147/nss.s178540 · Cited by 34
Acute Invasive Pulmonary Aspergillosis: Clinical Presentation and Treatment
Heylen, J., Vanbiervliet, Y., Maertens, J. A., Rijnders, B. J. A., & Wauters, J. (2024) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0043-1777769 · Cited by 41
“18,39,40 Almost all COPD patients with IPA are treated with steroids before and during hospitalization.”
BackgroundHalder, V., Porter, C. B. M., Chavez, A., & Shapiro, R. S. (2019) · Nature Protocols · doi:10.1038/s41596-018-0122-6 · Cited by 37
Native human and mouse skin infection models to study Candida auris-host interactions
Seiser, S., Arzani, H., Ayub, T., Phan-Canh, T., Staud, C., Worda, C., Kuchler, K., & Elbe-Bürger, A. (2024) · Microbes and Infection · doi:10.1016/j.micinf.2023.105234 · Cited by 29
Ленгерт, Е. В., Talnikova, E. E., Tuchin, V. V., & Svenskaya, Y. I. (2020) · Skin Pharmacology and Physiology · doi:10.1159/000511038 · Cited by 30
Zuani, M. D., Paolicelli, G., Zelante, T., Renga, G., Romani, L. R., Arzese, A., Pucillo, C. E. M., & Frossi, B. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02829 · Cited by 30
“albicans is responsible for more than one half of the cases of candidaemia, which mortality rates in Europe vary between 28 and 59% (6, 7).”
BackgroundScordino, F., Giuffrè, L., Barberi, G., Marino‐Merlo, F., Orlando, M. G., Giosa, D., & Romeo, O. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.00679 · Cited by 26
Aspergillus-specific antibodies – Targets and applications
Schubert, M., Spiegel, H., Schillberg, S., & Nölke, G. (2018) · Biotechnology Advances · doi:10.1016/j.biotechadv.2018.03.016 · Cited by 29
Willaert, R., Kayacan, Y., & Devreese, B. V. (2021) · Pathogens · doi:10.3390/pathogens10111397 · Cited by 27
Estimated Burden of Serious Fungal Diseases in Serbia
Arsić-Arsenijević, V. S., & Denning, D. W. (2018) · Journal of Fungi · doi:10.3390/jof4030076 · Cited by 24
“Documented invasive fungal infection outbreaks in Serbia stress the importance of education and prevention as a key aspect of SFD [58,59].”
BackgroundSelf-citationMuzaheed, M., Alshehri, B., Rabaan, A. A., El-Masry, O. S., Acharya, S., Alzahrani, F., Mutair, A. S. A., Alhumaid, S., Al‐Tawfiq, J. A., Muhammad, J., et al. (2021) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2021.11.014 · Cited by 23
Re-estimation of the burden of serious fungal diseases in Uganda
Bongomin, F., Kwizera, R., Namusobya, M. S., van Rhijn, N., Biraro, I. A., Kirenga, B., Meya, D. B., & Denning, D. W. (2024) · Therapeutic Advances in Infectious Disease · doi:10.1177/20499361241228345 · Cited by 21
Self-citationEstimated burden of fungal infections in Sweden
Özenci, V., Klingspor, L., Ullberg, M., Chryssanthou, E., Denning, D. W., & Kondori, N. (2019) · Mycoses · doi:10.1111/myc.12981 · Cited by 14
“29 A major reason is the limited availability of epidemiologi‐ cal data for fungal infections.”
BackgroundSelf-citationAcute invasive fungal sinusitis: Epidemiology and outcomes in the United States
Smith, S. S., Luong, A., Ramakrishnan, V. R., Tan, B. K., French, D. D., & Kern, R. C. (2021) · International Forum of Allergy & Rhinology · doi:10.1002/alr.22896 · Cited by 14
Scordino, F., Giuffrè, L., Felice, M. R., Orlando, M. G., Medici, M. A., Marino‐Merlo, F., & Romeo, O. (2019) · Infection Genetics and Evolution · doi:10.1016/j.meegid.2019.104068 · Cited by 13
Strategic Research Funding: A Success Story for Medical Mycology
Gow, N. A. R., Amin, T., McArdle, K., Brown, A. J. P., Brown, G. D., & Warris, A. (2018) · Trends in Microbiology · doi:10.1016/j.tim.2018.05.014 · Cited by 12
Fungal disease incidence and prevalence in Iraq – Preliminary estimates
Mohammad, K. A., Ismail, H. M., Shekhany, K. A. M., Yashooa, R. K., Younus, D. A., Abdullah, S. K., Al-Attraqchi, A. A. F., Aldabbagh, R., & Denning, D. W. (2024) · Journal de Mycologie Médicale · doi:10.1016/j.mycmed.2024.101516 · Cited by 15
Self-citationStephanoascus ciferrii Complex: The Current State of Infections and Drug Resistance in Humans
Cosio, T., Pica, F., Fontana, C., Pistoia, E. S., Favaro, M., Valsecchi, I., Zarabian, N., Campione, E., Botterel, F., & Gaziano, R. (2024) · Journal of Fungi · doi:10.3390/jof10040294 · Cited by 19
“Over the past five years, the LIFE portal has enabled the assessment of the global burden of severe fungal infections for more than 5.7 billion individuals, representing over 80% of the global population [7].”
BackgroundInfluentialRadonicic, V., Yvanoff, C., Villalba, M. I., Kasas, S., & Willaert, R. (2022) · Fermentation · doi:10.3390/fermentation8050195 · Cited by 10
Human Fungal Infections in Kuwait—Burden and Diagnostic Gaps
Alfouzan, W. A., Al-Wathiqi, F., Altawalah, H., Asadzadeh, M., Khan, Z., & Denning, D. W. (2020) · Journal of Fungi · doi:10.3390/jof6040306 · Cited by 9
Self-citationBrito, P. K. M. O., de Campos, G. Y., Guimarães, J. G., da Costa, L. S., de Moura, E. S., Chica, J. E. L., Roque‐Barreira, M. C., & da Silva, T. A. (2022) · Vaccines · doi:10.3390/vaccines10040620 · Cited by 9
“According to the Global Action Fund for Fungal Infections, the genus Cryptococcus has been responsible for clinical cases of cryptococcosis, which has highly impacted global public health over the last several decades [3,4].”
BackgroundSpecial considerations for the diagnosis and treatment of invasive pulmonary aspergillosis
McCarthy, M. W., & Walsh, T. J. (2017) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2017.1340835 · Cited by 8
“One study compared performance of the GMA assay with the BDG assay in sera from 105 patients with proven (n = 14) or probable (n = 91) IA, 97 hematology patients at risk for invasive fungal infections (IFIs), and 50 healthy blood donors [51].”
BackgroundInfluentialGenotypic diversity, virulence, and molecular genetic tools in Histoplasma
Sepúlveda, V. E., Goldman, W. E., & Matute, D. R. (2024) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00076-23 · Cited by 9
When to suspect and how properly early detect and treat patients with endemic mycoses
Colombo, A. L., Pietrobom, P. M. P., Santos, D. W. D. C. L., & Cáceres, D. H. (2025) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2025.101348 · Cited by 8
Mapping the Burden of Fungal Diseases in the United Arab Emirates
Dhaheri, F. A. A., Thomsen, J., Everett, D., & Denning, D. W. (2024) · Journal of Fungi · doi:10.3390/jof10050353 · Cited by 11
“Despite this impressive feat, many regions in the Middle East, North Africa, and Turkey (MENAT) remain under-mapped or not mapped at all, including the United Arab Emirates (UAE), due to the lack of published data [2,21].”
BackgroundSelf-citationSariyanti, M., AGUSTRIA, P. M., HERLAMBANG, W. F., Sinuhaji, B., Wıbowo, R. H., LESTARI, N., Nugraheni, E., & Sipriyadi, S. (2021) · Microbiology Indonesia · doi:10.5454/mi.15.1.4 · Cited by 6
“5% of the global population were affected by fungal disease (Denning 2017).”
InfluentialBongomin, F., Erima, B., Kwizera, R., & Odongo-Aginya, E. I. (2020) · Education Research International · doi:10.1155/2020/9468241 · Cited by 6
“*ough most deaths from fungal diseases are avoidable, public health authorities still neglect addressing the challenge posed by fungal diseases [4].”
BackgroundWhat is the elephant in the room when considering new therapies for fungal diseases?
Chaves, A. F. A., Xander, P. B., Romera, L. M. D., Fonseca, F. L. A., & Batista, W. L. (2021) · Critical Reviews in Microbiology · doi:10.1080/1040841x.2021.1876632 · Cited by 5
Drug repurposing for fungal infections
Mathuria, A., Ali, N., Kataria, N., & Mani, I. (2024) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2024.04.002 · Cited by 4
Mohana, P., Singh, A., Rashid, F., Singh, S., Kaur, K., Rana, R., Bedi, P. M. S., Bedi, N., Kaur, R., & Arora, S. (2024) · The Journal of Microbiology · doi:10.1007/s12275-024-00174-5 · Cited by 8
Azoles Used in Agriculture as Possible Cause of Azole-Resistance in Clinical Candida Isolates
Kaur, H., Yadav, A., Wadhwa, K., Jain, K., & Ghorai, S. M. (2021) · Biosciences Biotechnology Research Asia · doi:10.13005/bbra/2884 · Cited by 7
Beer, K. D., Blaney, D. D., Kadzik, M. E., Asiedu, K. B., Shieh, W., Bower, W. A., Jackson, B. R., Walke, H. T., & Chiller, T. M. (2018) · Current Fungal Infection Reports · doi:10.1007/s12281-018-0317-x · Cited by 4
Role of Antifungal Drugs in Combating Invasive Fungal Diseases
Dutt, K. (2019) · Wiley eBooks · doi:10.1002/9781119460053.ch5 · Cited by 5
Species Diversity and Distribution of Non-fumigatus Aspergillus Species in Ogasawara Islands, Japan
Tachikawa, R., Hagiuda, R., & Hirose, D. (2025) · Medical Mycology Journal · doi:10.3314/mmj.24-00017 · Cited by 3
Micosis de declaración obligatoria: utopía o realidad. Una cuestión olvidada por resolver
Fernández, N., & Davel, G. (2019) · Revista Argentina de Microbiología · doi:10.1016/j.ram.2019.04.001 · Cited by 3
Fungal infections: advances in diagnosis and treatment
Vijayaraman, R. S., & Pushpanathan, P. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821734-4.00011-3 · Cited by 2
Liu, Y., Ren, F., Li, S., Li, X., Shi, D., & Zhang, Z. (2024) · Infection and Drug Resistance · doi:10.2147/idr.s459378 · Cited by 3
Akinlawon, D. O., Osaigbovo, I. I., Yahaya, M., Makanjuola, O. B., Udoh, U. A., Nwajiobi-Princewill, P., Nwafia, I. N., Peter, J. Y., Asamoah, I. E., Peters, F., et al. (2024) · International Journal of Public Health · doi:10.3389/ijph.2024.1607731 · Cited by 1
COMPARATIVE EVALUATION OF THE EFFECTIVENESS OF PATHOGENETIC AND ETIOLOGICAL TREATMENT OF OTOMYCOSIS
Poladova, L. R. (2023) · Bulletin of Problems Biology and Medicine · doi:10.29254/2077-4214-2023-4-171-232-236 · Cited by 1
A atividade imunomoduladora de ArtinM sobre o curso da infecção por Cryptococcus gattii
Brito, P. K. M. O. (2019) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.17.2019.tde-30052019-151910 · Cited by 1
Fernandes, M. F. B. C. R. (2021) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-8881 · Cited by 3
Juglal, S. (2023) · DUT Open Scholar (Durban University of Technology) · doi:10.51415/10321/4829
Triple-Action Antifungal Topicals, Microbiologist's Alarm
Éric, K. I. (2023) · Asian Journal of Biology · doi:10.9734/ajob/2023/v19i1357
Luperini, R. S. (2023) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.17.2023.tde-17102023-105339
INVESTIGATION OF THE SPECTRUM OF PATHOGENS OF OTOMYCOSIS AND THEIR SENSITIVITY TO ANTIFUNGAL DRUGS
Poladova, L. R. (2024) · Azerbajdžanskij medicinskij žurnal · doi:10.34921/amj.2024.71.22.002
Poladova, L. R., & Vm, P. (2024) · Оториноларингология Восточная Европа · doi:10.34883/pi.2024.14.3.017
dos Reis, T. F., Delbaje, E., Pinzan, C. F., Bastos, R. W., Ackloo, S. Z., Fallah, S., Laflamme, B., Robbins, N., Cowen, L. E., & Goldman, G. H. (2025) · Microbiology Spectrum · doi:10.1128/spectrum.03318-24 · Cited by 2
“First-line treatment for IPA relies on the administration of broad-spectrum triazoles such as itraconazole, posaconazole, and voriconazole (VOR), with VOR being the drug of choice (14, 15).”
PREVALENCE OF SKIN MYCOSES IN GANJA, AZERBAIJAN REPUBLIC
oglu, M. A. H. (2025) · Актуальні проблеми сучасної медицини Вісник Української медичної стоматологічної академії · doi:10.31718/2077-1096.25.1.56
Occurrence of infections in dogs receiving ciclosporin in a single‐centre UK referral population
Dormon, S., Walker, J. J. A., Gallow, G., Goonan, L., Sparks, T. H., & Paul, A. (2026) · Journal of Small Animal Practice · doi:10.1111/jsap.70189
Goldman, G. H., Pinzan, C. F., Rocha, P. S., Ribeiro, M. M., da Graça-Filho, R. V., Savoldi, M., Sartorelli, S. M., Marciano, C. L., Cabral, H., Santos, R. S., et al. (2026) · Cell Reports · doi:10.1016/j.celrep.2026.117978
Metadata
- Authors
- Denning, D. W.
- Affiliations
- University of Manchester (GB)
- Corresponding author
- Denning, D. W.
- ORCID
- Denning, D. W.
- Venue
- European Journal of Clinical Microbiology & Infectious Diseases
- Published
- 2017-02-01
- Volume
- 36
- Issue
- 6
- Pages
- 923-924
- ISSN
- 0934-9723 (ISSN-L)
- 1435-4373
- OpenAlex
- W2585454635
- Cited by
- 67
- References
- 4
- Citations by year
- 2026: 2 · 2025: 4 · 2024: 11 · 2023: 5 · 2022: 3 · 2021: 11 · 2020: 9 · 2019: 11 · 2018: 8 · 2017: 3
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- European Journal of Clinical Microbiology & Infectious Diseases (publishedVersion)
- PubMed (publishedVersion)
- Research Explorer (The University of Manchester) (submittedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Public Health Policies and Education
- Keywords
- fungal diseases, fungal epidemiology, mycologists, disciplinary development
- MeSH terms
- Developing Countries, Humans, Mycology, Mycoses, Public Health, Bibliometrics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.